Korea Exchange · Healthcare
SAMSUNG PHARM. stock from India: price, numbers and tax
SAMSUNG PHARM. (001360) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
SAMSUNG PHARM. at a glance
- Price
- ₩1,376.00-₩58.00 (4.04%)
- Market cap
- ₩129.51B
- Day range
- ₩1,375.00 – ₩1,439.00
- P/E
- -0.95
- Dividend yield
- None
- Volume
- 302.63K
- 1 month
- +2.61%
- 6 months
- -24.44%
- YTD
- -10.07%
- 1 year
- -13.73%
- 5 years
- -75.04%
SAMSUNG PHARM. statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩46.1B | ₩44.3B | ₩52.0B | ₩51.8B | ₩54.9B |
| Gross profit | ₩14.6B | ₩19.8B | ₩23.0B | ₩24.6B | ₩9.3B |
| Operating income | −₩19.5B | −₩14.8B | −₩18.0B | −₩14.0B | −₩19.1B |
| Net income | ₩11.5B | −₩14.1B | −₩24.8B | −₩25.1B | −₩40.3B |
| Earnings per share | ₩122.66 | −₩156.21 | −₩333.83 | −₩337.30 | −₩547.68 |
| EBITDA | −₩18.1B | −₩11.7B | −₩21.7B | −₩22.0B | −₩36.5B |
| Total assets | ₩167.4B | ₩128.5B | ₩93.5B | ₩117.9B | ₩145.5B |
| Total debt | ₩17.7B | ₩5.2B | ₩595.5M | ₩2.0B | ₩2.1B |
| Cash and short-term investments | ₩16.2B | ₩10.4B | ₩4.3B | ₩56.0B | ₩64.4B |
| Shareholders' equity | ₩121.0B | ₩105.9B | ₩77.6B | ₩102.6B | ₩127.3B |
| Operating cash flow | −₩10.1B | −₩17.3B | −₩27.7B | −₩1.9B | −₩7.2B |
| Free cash flow | −₩10.1B | −₩17.7B | −₩40.4B | −₩4.9B | −₩11.2B |
| Capital expenditure | −₩53.9M | −₩380.7M | −₩12.8B | −₩3.0B | −₩4.1B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Whan In Pharm | 016580.KS | ₩10,180.00 | ₩188.17B |
| Ilsung Is | 003120.KS | ₩22,350.00 | ₩160.07B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Kyongbo Pharmaceutical | 214390.KS | ₩5,500.00 | ₩131.49B |
| Jeil Pharma | 002620.KS | ₩7,550.00 | ₩115.90B |
| HANDOK | 002390.KS | ₩8,600.00 | ₩111.72B |
| Enzychem Lifesciences | 183490.KQ | ₩990.00 | ₩83.79B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in SAMSUNG PHARM. from India
What SAMSUNG PHARM. does
SAMSUNG PHARM. Co., LTD. is a South Korean pharmaceutical company engaged in the manufacturing and distribution of a wide array of medical products. SAMSUNG PHARM. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell SAMSUNG PHARM. shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.